Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature.

Medicine - 25 Aug 2023

Guo Qiang, Feng Weiqiang, Hu Sheng, Ye Jiayue, Wang Silin, Su Lang, Zhang Yang, Zhang Deyuan, Zhang Wenxiong, Xu Jianjun, Wei Yiping

Abstract excerpt

RATIONALE: With the advancement of targeted therapies, epidermal growth factor receptor tyrosine kinase inhibitors have become the preferred initial treatment for patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is effective against exon 19 and 21 mutations as well as the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Bone Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboplatin

Share to Carcinoma, Non-Small-Cell Lung

Share to Pemetrexed

Share to Protein Kinase Inhibitors

Share to Tyrosine Kinase Inhibitors

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 37653755
DOI: 10.1097/MD.0000000000034545
PMCID: PMC10470715

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature.PMID 37653755Read ↗

Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.Semantic proximity Read ↗

De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.Semantic proximity Read ↗

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.Semantic proximity Read ↗

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasisSemantic proximity Read ↗

Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report.Semantic proximity Read ↗

Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung CancerSemantic proximity Read ↗

A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.Semantic proximity Read ↗

Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M-positive non-small cell lung cancer.Semantic proximity Read ↗

EGFR Mutation Subtype and Risk of Brain Metastases from Non-Small Cell Lung Cancer in the Osimertinib EraSemantic proximity Read ↗

Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.Semantic proximity Read ↗

Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.